Abstract: Angiogenesis is essential for lymphoma growth, progression and metastasis which is stimulated by many pro-angiogenic factors as basic Fibroblast Growth Factor (FGF), Vascular Endothelial Growth Factor (VEGF) and Platelet Derived Growth Factor (PDGF). This study aimed to delineate the role of angiogenic growth factors, basic FGF, VEGF and PDGF-bb in the patients with Non-Hodgkin Lymphoma (NHL) and Hodgkin Disease (HD) compared to healthy donors. The study included 94 patients, 54 of them diagnosed as NHL and 40 patients diagnosed as HD. The levels of basic FGF, VEGF and PDGF-bb in pre-treatment patients and in patients under chemo-radiotherapy (<8 cycles) were measured by Bio-Plex Pro assays. Twenty healthy donors were enrolled as controls. Our data show a significant increase in the levels of studied 3 factors in NHL pre-treatment patients compared to controls (p = 0.025, <0.001 and 0.02, respectively). These factors decreased significantly in whole patients under-treatment than pretreated ones (p<0.001 each). In HD, there was a significant increase of these factors in pretreated patients than controls (p<0.001 each). These factors significantly decreased in under-treatment patients than pretreatment (p≤0.001 each). VEGF was still significantly higher in under-treatment patients than controls (p<0.001) in NHL and HD. These factors were higher in patients with progressive course of lymphoma than those with complete or partial remission. FGF, VEGF and PDGF in lymphoma patients decreased significantly after chemo-radiotherapy but VEGF is still higher than controls. New anti-angiogenic strategies should be added to commonly used chemotherapy regimen in lymphoma.